口腔給藥系統市場、機會、成長動力、產業趨勢分析與預測，2024-2032

在糖尿病和心血管疾病盛行率不斷上升的推動下，2024年至2032年全球口腔給藥系統市場規模將以8.6%的複合年成長率擴大。

口腔給藥系統正在被設計為一種非侵入性的給藥替代方案，確保改善吸收和更快起效。透過利用口腔黏膜進行藥物輸送，這些系統提高了患者的依從性和便利性，特別是對於那些需要頻繁給藥或難以口服片劑的患者。根據世界衛生組織的數據，心血管疾病 (CVD) 導致全球死亡，每年約 1,790 萬人死亡。在這種背景下，口腔給藥系統將自己定位為一種有效的解決方案，有望實現藥物的快速吸收並提高患者對 CVD 管理的依從性。

市場分為產品類型、應用、系統類型、最終用途和區域。

就產品類型而言，到 2032 年，口腔給藥系統產業的口腔凝膠細分市場將以相當大的複合年成長率成長。口腔凝膠專為透過口腔黏膜控制和持續釋放藥物而配製，旨在提高吸收和治療效果。凝膠配方的持續進步是微調釋放曲線和成分穩定性，進一步增強系統的功效。

從應用來看，神經系統疾病領域的口腔給藥系統市場佔有率預計將在 2024 年至 2032 年期間上升。透過頰黏膜輸送藥物，這些系統可確保快速吸收並避免首過代謝，這是中樞神經系統藥物的關鍵因素。這種方法不僅可以加強神經系統疾病的管理，還可以確保提高生物利用度和患者依從性。

從地區來看，由於患者對替代給藥途徑的偏好不斷增加，預計歐洲口腔給藥系統產業規模將在 2024 年至 2032 年間出現顯著的複合年成長率。口腔給藥可加快吸收並最大限度地減少胃腸道副作用，從而提高藥物依從性。此外，區域進步的重點是開發更有效的配方和技術，以提高藥物穩定性和釋放曲線。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 對非侵入性給藥方法的需求不斷增加
    • 口腔給藥技術的進步
    • 需要長期藥物治療的慢性病盛行率上升
    • 對口腔給藥系統的認知與接受度不斷提高
  • 產業陷阱與挑戰
    • 由於患者不適，市場接受度有限
    • 開發和生產成本高
• 成長潛力分析
• 報銷場景
• 未來市場趨勢
• 監管環境
• 技術景觀
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

• 主要趨勢
• 口含片
• 頰膜
• 口腔凝膠
• 口腔噴霧劑
• 頰貼片

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 疼痛管理
• 荷爾蒙替代品
• 心血管疾病
• 神經系統疾病
• 呼吸系統疾病
• 成癮治療
• 心理健康障礙

第 7 章：市場估計與預測：按系統類型，2021 - 2032 年

• 主要趨勢
• 矩陣系統
• 水庫系統

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 家庭護理設置
• 專科診所
• 門診手術中心
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• Collegium Pharmaceutical, Inc.
• Endo International plc
• Galderma SA
• Indivior plc
• Johnson and Johnson Services, Inc.
• Kyowa Kirin Co., Ltd.
• Mallinckrodt plc
• Neurelis, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceuticals Company Limited
• Teva Pharmaceutical Industries Ltd.

Global Buccal Drug Delivery Systems Market size will expand at an 8.6% CAGR from 2024 to 2032, fueled by the increasing prevalence of diabetes and cardiovascular diseases.

Buccal drug delivery systems are being crafted as a non-invasive alternative for medication administration, ensuring improved absorption and quicker action onset. By utilizing the mouth's mucous membranes for drug delivery, these systems boost patient compliance and convenience, especially for those needing frequent doses or struggling with oral tablets. As per WHO, cardiovascular diseases (CVDs) lead to global mortality, accounting for around 17.9 million deaths annually. In this context, buccal drug delivery systems are positioning themselves as a potent solution, promising swift medication absorption and heightened patient compliance for CVD management.

The market is segregated into product type, application, system type, end-use, and region.

In terms of product type, the buccal gels segment in the buccal drug delivery systems industry will grow at a considerable CAGR through 2032. This surge is driven by the rising demand for innovative medication administration methods. Formulated for controlled and sustained drug release via the buccal mucosa, buccal gels aim to boost absorption and therapeutic effectiveness. Ongoing advancements in gel formulations are fine-tuning release profiles and ingredient stability, further amplifying the efficacy of the systems.

By application, the buccal drug delivery systems market share from the neurological disorders segment is projected to rise from 2024 to 2032. This growth is attributed to the rising demand for specialized formulations and technologies. By delivering drugs via the buccal mucosa, these systems ensure rapid absorption and sidestep first-pass metabolism, a critical factor for central nervous system medications. Such an approach not only bolsters the management of neurological conditions but also guarantees improved bioavailability and patient adherence.

Regionally, the Europe buccal drug delivery systems industry size is projected to witness a significant CAGR between 2024 and 2032 due to the growing patient preference for alternative routes of administration. Buccal drug delivery enhances medication adherence by providing faster absorption and minimizing gastrointestinal side effects. Furthermore, regional advancements are focused on crafting more potent formulations and technologies to elevate drug stability and release profiles.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for non-invasive drug delivery methods
    • 3.2.1.2 Advancements in buccal drug delivery technologies
    • 3.2.1.3 Rising prevalence of chronic diseases requiring long-term medication
    • 3.2.1.4 Growing awareness and acceptance of buccal drug delivery systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited market acceptance due to patient discomfort
    • 3.2.2.2 High development and production costs
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Buccal tablets
• 5.3 Buccal films
• 5.4 Buccal gels
• 5.5 Buccal sprays
• 5.6 Buccal patches

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Hormone replacement
• 6.4 Cardiovascular diseases
• 6.5 Neurological disorders
• 6.6 Respiratory disorders
• 6.7 Addiction treatment
• 6.8 Mental health disorders

Chapter 7 Market Estimates and Forecast, By System Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Matrix systems
• 7.3 Reservoir systems

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Homecare settings
• 8.4 Specialty clinics
• 8.5 Ambulatory surgical centers
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Collegium Pharmaceutical, Inc.
• 10.4 Endo International plc
• 10.5 Galderma SA
• 10.6 Indivior plc
• 10.7 Johnson and Johnson Services, Inc.
• 10.8 Kyowa Kirin Co., Ltd.
• 10.9 Mallinckrodt plc
• 10.10 Neurelis, Inc.
• 10.11 Novartis AG
• 10.12 Pfizer Inc.
• 10.13 Sanofi
• 10.14 Takeda Pharmaceuticals Company Limited
• 10.15 Teva Pharmaceutical Industries Ltd.